Arpeggio Biosciences raises $20M in latest offering
BizWest—Arpeggio Biosciences, a University of Colorado Boulder startup that works in the development of pharmaceuticals, has raised about two-thirds of what it expects to collect in its latest investment offering.
The University of Colorado Connection
Arpeggio Biosciences is a Boulder-based biotechnology company developing a high-throughput transcriptomics platform to map how chemical compounds influence gene expression across entire biological networks. Founded in 2017 by Joey Azofeifa (CU Boulder BioFrontiers Institute) and Robin Dowell (CU Boulder BioFrontiers Institute and Molecular, Cellular & Developmental Biology), the company originated from research conducted at CU's BioFrontiers Institute. Arpeggio's platform combines nascent RNA sequencing with machine learning to profile the immediate effects of drugs on gene expression, enabling the discovery of novel therapeutic targets for diseases such as cancer, chronic kidney disease and neurodegeneration. The company has raised over $20 million in funding, including a $17 million Series A round in 2022 led by Builders VC.
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.